Use of enoxaparin in emergency room for improving outcomes of primary percutaneous coronary interventions for acute myocardial infarction

Indian Heart Journal

Volumn 60, Issue 1, 2008, Pages 39-44

  Abhyankar, Atul D ^a,c   Pothiawala, Sohil E ^a   Kazi, Girish J ^b   Jha, Mahendu J ^b   Petrolwala, Mukur ^b  

^a Heartfirst Cardiac and Vascular Centre   (India)

^b Mahavir Heart Institute   (India)

^c NONE   (India)

Author keywords

Acute myocardial infarction; Emergency room; Enoxaparin; Primary percutaneous coronary intervention

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; CLOPIDOGREL; ENOXAPARIN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; TIROFIBAN;

ACUTE HEART INFARCTION; ADULT; ARTERY DIAMETER; ARTICLE; CARDIOGENIC SHOCK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DRUG ELUTING STENT; EMERGENCY WARD; HEART CATHETERIZATION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; PERCUTANEOUS CORONARY INTERVENTION; ST SEGMENT ELEVATION;

ADULT; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTICOAGULANTS; COHORT STUDIES; DRUG ADMINISTRATION SCHEDULE; EMERGENCY SERVICE, HOSPITAL; ENOXAPARIN; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; TREATMENT OUTCOME;

EID: 48749086828     PISSN: 00194832     EISSN: 00194832     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. DeWood MA, Spores J, Notske R, et al. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med 1980;303:897-902.
2. O'Neill W, Timmis GC, Bourdillon PD, et al . A prospective randomized clinical trial of intracoronary streptokinase versus coronary angioplasty for acute myocardial infarction. N Engl J Med 1986;314:812-818.
3. Zijlstra F, de Boer MJ, Hoorntje JC, Reiffers S, Reiber JH, Suryapranata H. A comparison of immediate coronary angioplasty with intravenous streptokinase in acute myocardial infarction. N Engl J Med 1993;328:680-684.
4. Grines CL, Browne KF, Marco J, et al. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. The Primary Angioplasty in Myocardial Infarction Study Group. N Engl J Med 1993;328:673-679.
5. Braunwald E, Antman EM, Beasley JW, et al. American College of Cardiology/American Heart Association. Committee on the Management of Patients with Unstable Angina. J Am Coll Cardiol 2002;40:1366-1374.
6. Wong GC, Giugliano RP, Antman EM. Use of low-molecular-weight heparins in the management of acute coronary syndromes and percutaneous coronary intervention. JAMA 2003;289:331-342.
7. Hirsh J, Levine MN. Low molecular weight heparin. Blood 1992;79:1-17.
8. Samama MM, Bara L, Gerotziafas GT. Mechanisms for the antithrombotic activity of low molecular weight heparins (LMWH). Haemostasis 1994;24:105-117.
9. Weitz JI. Low-molecular-weight heparin. N Engl J Med 1997;332:1330-1335.
10. Weitz JI. Low-molecular-weight heparins. N Engl J Med 1997;337:698.
11. Cohen M, Demers C, Gurfinkel E, et al. A comparison of low molecular weight heparin with unfractionated heparin for unstable coronary disease. N Engl J Med 1997;337:447-452.
12. Antman EM, McCabe CH, Gurfinkel E, et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q wave myocardial infarction: results of the Thrombolysis in Myocardial Infarction TIMI 11B trial. Circulation 1999;100:1593-1601.
13. Antman EM, Cohen M, McCabe CH, et al. Enoxaparin is superior to unfractionated heparin for preventing clinical events at one year follow-up of TIMI 11B and ESSENCE. Eur Heart J 2002;23:308-314.
14. Borentain M, Montalescot G, Bouzamondo A, et al. Intravenous low-molecular-weight heparin versus unfractionated heparin in percutaneous coronary angioplasty: A meta-analysis. Eur Heart J 2003;24(Abstr, Suppl):541.
15. Rabah MM, Premmereur J, Graham M, et al. Usefulness of intravenous enoxaparin for percutaneous coronary intervention in stable angina pectoris. Am J Cardiol 1999;84:1392-1395.
16. Dudek D, Zymek P, Bartus S, Dubiel JS. The assessment of safety of enoxaparin administration during percutaneous transluminal coronary angioplasty after ticlopidine pretreatment. Application of low molecular weight heparins in prevention of coronary micro-embolization. Przegl 2001;58:484-486.
17. Kereiakes DJ, Grines C, Fry E, et al. for the NICE 1 and NICE 4 Investigators. National Investigators Collaborating on Enoxaparin. J Invasive Cardiol 2001;13:272-278.
18. Choussat R, Montalescot G, Collet JP, et al. A unique, low dose of intravenous enoxaparin in elective percutaneous coronary intervention. J Am Coll Cardiol 2002; 40:1943-1950.
19. Chen WH, Lau CP, Lau YK, et al. Stable and optimal anticoagulation is achieved with a single dose of intravenous enoxaparin in patients undergoing percutaneous coronary intervention. J Invasive Cardiol 2002;14:439-442.
20. Pena PS, Montalescot G, Hulot JS, et al. Intravenous enoxaparin in patients undergoing percutaneous coronary intervention. Circulation 2004(Suppl);110:III-616.
21. Korovesis S, Karvouni E, Karabinos I, et al. Comparison of enoxaparin and unfractionated heparin in coronary angioplasty. Hellenic J Cardiol 2005;46:46-51.
22. Antman EM, Cohen M, Radley D, et al. Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction: TIMI 11B-ESSENCE meta-analysis. Circulation 1999;100:1602-1608.
23. Cohen M, Demers C, Gurfinkel EP, et al . A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med 1997;337:447-452.
24. Antman EM, McCabe CH, Gurfinkel EP, et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 11B trial. Circulation 1999;100:1593-1601.
25. Petersen JL, Mahaffey KW, Hasselblad V, et al. Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for anti-thrombin therapy in non-ST segment elevation acute coronary syndromes JAMA 2004;292:89-96.
26. Cohen M, Theroux P, Frey MJ, et al. Anti-thrombotic combination using tirofiban and enoxaparin: the ACUTE II study. Circulation 2000;102:II-826.
27. Goodman SG, Fitchett DH, Armstrong P, et al. Randomized evaluation of the safety and efficacy of enoxaparin versus unfractionated heparin in high risk patients with non ST segment elevation acute coronary syndromes receiving the GP IIb/IIIa receptor inhibitor eptifibatide. Circulation 2003;107:238-244.
28. Wolak A, Ayzenberg Y, Cafri C, et al. Can enoxaparin safely replace unfractionated heparin during coronary intervention in acute coronary syndromes? Int J Cardiol 2004;96(2):151-5 (ISSN: 0167-5273)
29. Blazing MA, de Lemos JA, White HD, et al. Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial. JAMA 2004;292(1):55-64 (ISSN: 1538-3598).
30. David S. Lee, Deepak L Bhatt, David J Moliterno, et al . The Combination of Enoxaparin, Glycoprotein IIb/IIIa Inhibitors and an Early Invasive Approach among Acute Coronary Syndrome Patients. J Invasive Cardiol 2004;16(2):46-51.
31. th Annual Scientific Session; March 11-14, 2006; Atlanta, Georgia. Abstract 422-9.
32. Antman EM, Morrow DA, McCabe CH, et al. for the ExTRACT-TIMI 25 Investigators. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. N Engl J Med 2006;354:1477-1488.
33. Ross AM, Molhoek P, Lundergan C, et al. Randomized comparison of enoxaparin, a low-molecular-weight heparin, with unfractionated heparin adjunctive to recombinant tissue plasminogen activator thrombolysis and aspirin: second trial of Heparin and Aspirin Reperfusion Therapy (HART II) Circulation 2001;104(6):648-52.
34. Simoons M, Krzeminska-Pakula M, Alonso A, et al. Improved reperfusion and clinical outcome with enoxaparin as an adjunct to streptokinase thrombolysis in acute myocardial infarction. The AMI-SK study. Eur Heart J 2002;23(16):1282-90.
35. ON-TIME: Ongoing Tirofiban in Myocardial Infarction Evaluation.
36. Montalescot G, Barragan P, Wittenberg O, et al. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 2001;344:1895-1903.
37. Cohen M, Theroux P, Weber S, et al . Combination therapy with tirofiban and enoxaparin in acute coronary syndromes. Int J Cardiol 1999;71:273-281.
38. Ferguson J, Antman E, Bates E, et al. for the NICE 3 Investigators. The use of enoxaparin and IIb/IIIa antagonists in acute coronary syndromes, including PCI: The NICE 3 Study (Abstr). Am J Cardiol 2000;86(Suppl 18A):16I.
39. Kereiakes J, Fry E, Barr L, et al. Enoxaparin-abciximab combination for percutaneous coronary intervention: Final results of the NICE 4 Trial (Abstr). Am J Cardiol 2000;86(Suppl 18A):14I.